Folate Receptor Alpha Antibody Conjugate Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved therapeutic methods that provide safe and effective doses of therapeutic conjugates directed to folate receptor alpha (FOLR1) for treating cancer and other conditions, as existing methods lack efficacy and safety.
Innovation Solution
The development of antibody conjugates that selectively bind folate receptor alpha (FOLR1) linked to payload moieties, administered in specific dosing schedules and doses, such as initial doses of 5.2 mg/kg and subsequent doses of 4.3 mg/kg, with the option of further doses, to treat cancer and other conditions like autoimmune diseases and inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic conjugates directed to FOLR1 are administered, then cancer treatment is attempted, but efficacy and safety are insufficient
Solution Approach 1:
The antibody conjugate is designed to deliver the cytotoxic payload specifically to FOLR1-expressing cancer cells through selective binding, concentrating the therapeutic effect locally at the tumor site while minimizing exposure to healthy tissues. This targeted delivery approach resolves the contradiction by enhancing treatment efficacy at the target site while reducing systemic toxicity.
Solution Approach 2:
The patent optimizes multiple parameters including the antibody structure, linker chemistry, and payload characteristics to achieve the desired balance between efficacy and safety. By carefully adjusting these parameters, the conjugate achieves sufficient potency against cancer cells while maintaining an acceptable safety profile through controlled release and targeted delivery.
2Reliability
If high doses of therapeutic conjugates are administered to improve efficacy, then treatment effectiveness increases, but safety and toxicity profile deteriorate
Solution Approach 1:
The antibody component serves as an intermediary that selectively binds to FOLR1 on cancer cells, mediating the delivery of the cytotoxic payload only to the intended target. This intermediary mechanism allows for effective cancer cell killing at lower overall doses, thereby improving the therapeutic index by reducing side effects while maintaining treatment effectiveness.
Solution Approach 2:
The conjugate utilizes the natural internalization pathway of the FOLR1-folate complex to deliver the payload into the cancer cell. The cell's own folate uptake mechanism is harnessed to facilitate payload entry, enabling effective intracellular delivery without requiring high extracellular concentrations of the conjugate, thus reducing systemic toxicity.
3Ease of manufacture
If non-specific antibody conjugates are used, then manufacturing is simpler, but treatment precision and efficacy are reduced
Solution Approach 1:
The patent employs a modular conjugate design where a well-characterized antibody platform with known specificity for FOLR1 is combined with a standardized linker-payload module. This universal approach allows for consistent manufacturing processes while maintaining high targeting specificity, as the antibody component provides the necessary precision and the modular design facilitates reproducible conjugation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody conjugates effectively treat cancer by selectively targeting folate receptor alpha, providing a safe and effective treatment regimen that reduces tumor volume and improves patient outcomes.
Implementation Method 1
antibody conjugates that selectively bind folate receptor alpha (FOLRα or FOLR1)
Implementation Method 2
a folate receptor has been shown to be a significant cofactor for cellular entry of viruses
Data Source
AI summary
The present disclosure relates to therapies with antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs. Also provided are methods of using the combinations with antibody conjugates and compositions thereof, such as in therapeutic and diagnostic methods.